Back to search

National and Kapodistrian University of Athens

Drug design of novel selective inhibitors targeting lipoxygenase enzyme and molecular study on the mechanism of action of anti-hypertensive drugs

Abstract

dc:description

In this thesis we employed a combination of theoretical and experimental methods to investigate the molecular activity of potent and commercially available drugs. In the first axis of this thesis, in silico calculations have been performed to discover potential inhibitors targeting human 5-lipoxygenase (5-LOX). 5-LOX is a popular enzyme responsible for the release of pro-inflammatory agents in the cell. It is associated to a variety of different diseases, such as asthma, Alzheimer’s and cancer, while the only commercially available inhibitor targeting the enzyme and prescribed for the treatment of asthma, zileuton, shows an unfavorable pharmacokinetic profile and causes liver toxicity. Thus, our aim was to discover novel compounds targeting 5-LOX that bind to the enzyme in the same manner as zileuton. The rationale for designing these compounds commenced by repurposing all the natural and artificial sweeteners for their action towards LOX, where aspartame was discovered as the most prominent LOX inhibitor. To eliminate aspartame’s metabolic products because of concerns for their safety, we designed a series of 12 compounds based on aspartame’s structural part that were evaluated with in silico and in vitro methods. The results pinpointed that two of the compounds could exert significant inhibitory activity towards 5-LOX. In the second axis of this thesis, the commercially available antihypertensive drug, irbesartan, was studied aiming to improve its pharmacological profile and unveil insights concerning its mechanism of action. The predominant hypothesis for the latter suggests that the drug initially enters the membrane and then slowly diffuses towards its receptor, rather than directly entering to the transmembrane receptor. Hence, irbesartan was encapsulated in a 2-hydroxypropyl-β-cyclodextrin carrier to improve its pharmacological profile, while its molecular interactions as well as its release to the lipid bilayers were investigated using in silico and NMR methods. Finally, this investigation pinpointed irbesartan’s release from the cyclodextrin carrier, while the most prominent conformation of the drug into the lipid bilayers was unveiled.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Chontzopoulou, Eleni
  • Χοντζοπούλου, Ελένη

Subjects

dc:subject × 14

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/57239

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Chontzopoulou, Eleni; Χοντζοπούλου, Ελένη. Drug design of novel selective inhibitors targeting lipoxygenase enzyme and molecular study on the mechanism of action of anti-hypertensive drugs. National and Kapodistrian University of Athens, 2024. http://hdl.handle.net/10442/hedi/57239